The U.S. Food and Drug Administration approved Evofem Biosciences Inc.’s Phexxi (lactic acid, citric acid and potassium bitartrate) vaginal gel for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.

The U.S. Supreme Court considered a bid by Donald Trump’s administration to implement rules allowing employers to obtain religious exemptions from an Obamacare requirement that health insurance that they provide to employees covers women’s birth control.

Amphora has the opportunity to completely disrupt the birth control market with a new viscous and bioadhesive contraceptive.

The Bill & Melinda Gates Foundation granted Watertown, Massachusetts-based Lyndra Therapeutics a $13 million grant to develop a once-a-month oral contraceptive.

Evofem Biosciences shares rose 38 percent after the company’s birth control gel showed effectiveness in a late-stage study, bringing the first hormone-free contraceptive close to approval.

Agile Therapeutics Inc.’s shares sank 75 percent after the drug developer said it expects to pursue what could be a prolonged appeal against health regulators’ issues over the company’s chief experimental product, a contraceptive patch.

Teva Pharmaceuticals Inc. made more cuts in the United States, this time to real estate holdings. To save money, the company will close its offices in Washington, D.C. and New York City. No jobs were reported to be lost from the cuts.

At least half the world’s population is unable to access essential health services and many others are forced into extreme poverty by having to pay for healthcare they cannot afford, the World Health Organization said.

Teva Pharmaceutical Industries Ltd. is close to a deal to sell its women’s health assets outside the United States to private equity firm CVC Capital Partners, the Fly reported, citing Bloomberg.

President Donald Trump signed a resolution that will allow U.S. states to restrict how federal funds for contraception and reproductive health are spent.